Table 4 Comparison of nephrotoxicity during cisplatin-based chemotherapy
|  | All patients | Pretreatment eGFR ≥60 mL/min/1.73m2 | Pretreatment eGFR < 60 mL/min/1.73m2 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Course | % Baseline eGFR impairment | Pretreatment eGFR ≥60 mL/min/1.73m2 (n = 119) impaird patient /n (%) | Pretreatment eGFR < 60 mL/min/1.73 m2 (n = 125) impaird patient /n (%) | p | Bilateral functioning kidneys (n = 83) impaird patient /n (%) | Solitary functioning kidney (n = 36) impaird patient /n (%) | p | Bilateral functioning kidneys (n = 45) impaird patient /n (%) | Solitary functioning kidney impaird patient /n (%) | p |
post 1st course | >  10% impairment | 38/119 (31.9%) | 23/125 (18.4%) | 0.015 | 28/83 (33.7%) | 10/36 (27.7%) | 0.52 | 9/45 (20.0%) | 15/80 (18.7%) | 0.73 |
>  20% impairment | 19/119 (15.9%) | 10/125 (8.0%) | 0.054 | 15/83 (18.0%) | 4/36 (11.1%) | 0.34 | 6/45 (13.3%) | 5/80 (6.2%) | 0.17 | |
>  30% impairment | 4/119 (3.4%) | 4/125 (3.2%) | 0.94 | 3/83 (3.6%) | 1/36 (2.7%) | 0.81 | 3/45 (6.6%) | 2/80 (2.5%) | 0.098 | |
post 2nd course | >  10% impairment | 29/104 (27.8%) | 17/110 (14.5%) | 0.026 | 20/72 (27.7%) | 9/32 (28.1%) | 0.97 | 10/42 (23.8%) | 7/68 (10.2%) | 0.056 |
>  20% impairment | 13/104 (12.5%) | 6/110 (5.4%) | 0.070 | 9/72 (12.5%) | 4/32 (12.5%) | 1.00 | 4/42 (9.5%) | 2/68 (2.9%) | 0.14 | |
>  30% impairment | 6/104 (5.8%) | 3/110 (2.7%) | 0.26 | 4/72 (5.5%) | 2/32 (6.2%) | 0.88 | 2/42 (4.7%) | 1/68 (1.4%) | 0.30 | |
post 3rd course | >  10% impairment | 29/78 (37.2%) | 15/82 (18.3%) | 0.011 | 17/54 (31.4%) | 12/27 (44.4%) | 0.25 | 8/24 (33.3%) | 7/58 (12.1%) | 0.023 |
>  20% impairment | 18/78 (23.0%) | 7/82 (8.5%) | 0.015 | 14/54 (25.9%) | 4/27 (14.8%) | < 0.001 | 4/24 (16.6%) | 3/58 (5.2%) | 0.091 | |
>  30% impairment | 5/78 (6.4%) | 2/82 (2.4%) | 0.23 | 2/54 (3.7%) | 3/27 (11.1%) | 0.19 | 2/24 (8.3%) | 0/58 (0.0%) | 0.026 | |
post 4th course | >  10% impairment | 26/59 (44.1%) | 13/59 (22.0%) | 0.010 | 17/39 (43.6%) | 9/20 (45.0%) | 0.91 | 4/20 (20.0%) | 9/39 (23.0%) | 0.78 |
>  20% impairment | 12/59 (20.3%) | 3/59 (5.1%) | 0.028 | 9/39 (23.0%) | 3/20 (15.0%) | 0.46 | 2/20 (10.0%) | 1/39 (2.5%) | 0.21 | |
>  30% impairment | 7/59 (11.9%) | 1/59 (1.7%) | 0.012 | 5/39 (12.8%) | 2/20 (10.0%) | 0.75 | 1/20 (5.0%) | 0/39 (0.0%) | 0.16 | |
during all courses | >  10% impairment | 56/119 (47.1%) | 32/125 (25.6%) | < 0.001 | 39/83 (46.9%) | 17/36 (47.2%) | 0.98 | 16/45 (33.3%) | 18/80 (22.5%) | 0.14 |
>  20% impairment | 25/119 (21.0%) | 17/125 (13.6%) | 0.125 | 18/83 (21.6%) | 7/36 (19.4%) | 0.78 | 10/45 (22.2%) | 7/80 (8.7%) | 0.034 | |
>  30% impairment | 16/119 (13.4%) | 7/125 (5.6%) | 0.036 | 11/83 (13.2%) | 5/36 (13.8%) | 0.92 | 5/45 (11.1%) | 3/80 (3.8%) | 0.11 | |